Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Firms Must Be Proactive About Live-Case Demo Plans For IDE Devices – FDA Draft Guidance

This article was originally published in The Gray Sheet

Executive Summary

FDA has released a draft guidance on the information that a device manufacturer should submit in an investigational device exemption application or supplement if it wants the device to be part of a live case demonstration.

You may also be interested in...



Lights, Camera … Surgery? FDA Lays Out IDE Live Presentation Rules

New final guidance from the US FDA sets out the agency’s expectations for the use of live-case presentations during device clinical trials, focusing on patient protection.

Live Transmission Of TAVR Found Safe, And More From Annual SCAI Conference

Interventional cardiologists presented new data at the annual meeting of The Society for Cardiovascular Angiography and Interventions supporting the safe use of live video transmission of transcatheter aortic valve replacement cases, and results from other late-breaking clinical trials.

California Court’s Inaction On TiO2 Prop 65 First Amendment Case Breeds New Lawsuits

The Personal Care Products Council seeks to stem the rising tide of titanium dioxide Proposition 65 lawsuits, requesting that a California court prohibit the state’s Attorney General and private enforcers from filing and/or prosecuting new suits against cosmetics companies failing to warn about potential TiO2 exposure.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032920

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel